Posts Tagged ‘bimagrumab’

OW2021: Building a Bridge to the Future of Obesity Care

November 2, 2021 — Monday was quite an opening day for ObesityWeek 2021. Starting with the lived experience, the meeting then moved quickly into some serious science, clinical care, and policy discussions. But one of the most impressive sessions of the day gave us a “tour de force” of future options under development for obesity care. Our friend Mike […]

Tirzepatide Shows Good Weight Outcomes in Diabetes

October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]

A Spark of New Life for Bimagrumab in Obesity

September 27, 2021 — It was an exciting possibility. At ObesityWeek 2019, Novartis scientist Laura Coleman presented fascinating results for an experimental drug, bimagumide, in obesity. In a phase 2 study, it yielded impressive improvements in body composition for people with obesity. It wasn’t just making people lose body fat. It helped them also gain muscle mass. Then, it […]

Bimagrumab: Hesitancy and Promise in Obesity Care

January 26, 2021 — Innovation in obesity care has come a long way. Back in 2010, Sanofi was smarting from the spectacular failure of rimonabant and big pharma was closing down research programs in obesity. But Novo Nordisk forged ahead with an ambitious program and now has a successful portfolio in obesity care to show for it. Nonetheless, we […]

More Than One Trick in Obesity Innovation

June 19, 2020 — In pharmaceuticals, a one-trick pony is doomed to oblivion. Some companies have a big hit with a successful drug and then struggle to follow up with more innovation. So patents expire and sales dwindle. The company with one-trick innovation fades away. But with solid clinical trial results announced yesterday for two new drugs in obesity, […]

Tantalizing: Bimagrumab, Obesity, and Body Composition

January 6, 2020 — It was a stunning and unique result that seemed to come out of nowhere at ObesityWeek late last year. A new drug, bimagrumab, yielded a 21 percent reduction in fat mass after 48 weeks. But lean body mass went up by 3.6 percent. This result is distinctly different from what usually happens in obesity treatment. […]

ObesityWeek: Emerging Anti-Obesity Medicines

November 5, 2019 — Success begets success. That’s a core message we’re taking away from a late-breaking forum on emerging anti-obesity medicines. Pharmaceutical researchers reviewed an impressive range of innovations that promise to set a higher bar for effective obesity care. All of this came before ObesityWeek kicks into high gear today. Building Upon Success Mads Tang-Christensen opened the […]